The complex role of tumor-infiltrating macrophages. 2022

Anthos Christofides, and Laura Strauss, and Alan Yeo, and Carol Cao, and Alain Charest, and Vassiliki A Boussiotis
Division of Hematology-Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.

Long recognized as an evolutionarily ancient cell type involved in tissue homeostasis and immune defense against pathogens, macrophages are being re-discovered as regulators of several diseases, including cancer. Tumor-associated macrophages (TAMs) represent the most abundant innate immune population in the tumor microenvironment (TME). Macrophages are professional phagocytic cells of the hematopoietic system specializing in the detection, phagocytosis and destruction of bacteria and other harmful micro-organisms, apoptotic cells and metabolic byproducts. In contrast to these healthy macrophage functions, TAMs support cancer cell growth and metastasis and mediate immunosuppressive effects on the adaptive immune cells of the TME. Cancer is one of the most potent insults on macrophage physiology, inducing changes that are intimately linked with disease progression. In this Review, we outline hallmarks of TAMs and discuss the emerging mechanisms that contribute to their pathophysiological adaptations and the vulnerabilities that provide attractive targets for therapeutic exploitation in cancer.

UI MeSH Term Description Entries
D008264 Macrophages The relatively long-lived phagocytic cell of mammalian tissues that are derived from blood MONOCYTES. Main types are PERITONEAL MACROPHAGES; ALVEOLAR MACROPHAGES; HISTIOCYTES; KUPFFER CELLS of the liver; and OSTEOCLASTS. They may further differentiate within chronic inflammatory lesions to EPITHELIOID CELLS or may fuse to form FOREIGN BODY GIANT CELLS or LANGHANS GIANT CELLS. (from The Dictionary of Cell Biology, Lackie and Dow, 3rd ed.) Bone Marrow-Derived Macrophages,Monocyte-Derived Macrophages,Macrophage,Macrophages, Monocyte-Derived,Bone Marrow Derived Macrophages,Bone Marrow-Derived Macrophage,Macrophage, Bone Marrow-Derived,Macrophage, Monocyte-Derived,Macrophages, Bone Marrow-Derived,Macrophages, Monocyte Derived,Monocyte Derived Macrophages,Monocyte-Derived Macrophage
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D010587 Phagocytosis The engulfing and degradation of microorganisms; other cells that are dead, dying, or pathogenic; and foreign particles by phagocytic cells (PHAGOCYTES). Phagocytoses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D059016 Tumor Microenvironment The milieu surrounding neoplasms consisting of cells, vessels, soluble factors, and molecules, that can influence and be influenced by, the neoplasm's growth. Cancer Microenvironment,Cancer Microenvironments,Microenvironment, Cancer,Microenvironment, Tumor,Microenvironments, Cancer,Microenvironments, Tumor,Tumor Microenvironments
D018450 Disease Progression The worsening and general progression of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis. Clinical Course,Clinical Progression,Disease Exacerbation,Exacerbation, Disease,Progression, Clinical,Progression, Disease

Related Publications

Anthos Christofides, and Laura Strauss, and Alan Yeo, and Carol Cao, and Alain Charest, and Vassiliki A Boussiotis
January 1979, Advances in experimental medicine and biology,
Anthos Christofides, and Laura Strauss, and Alan Yeo, and Carol Cao, and Alain Charest, and Vassiliki A Boussiotis
November 2020, Cancer immunology, immunotherapy : CII,
Anthos Christofides, and Laura Strauss, and Alan Yeo, and Carol Cao, and Alain Charest, and Vassiliki A Boussiotis
February 2022, Biology,
Anthos Christofides, and Laura Strauss, and Alan Yeo, and Carol Cao, and Alain Charest, and Vassiliki A Boussiotis
October 2013, Immunotherapy,
Anthos Christofides, and Laura Strauss, and Alan Yeo, and Carol Cao, and Alain Charest, and Vassiliki A Boussiotis
January 2020, Advances in experimental medicine and biology,
Anthos Christofides, and Laura Strauss, and Alan Yeo, and Carol Cao, and Alain Charest, and Vassiliki A Boussiotis
June 2010, BMC immunology,
Anthos Christofides, and Laura Strauss, and Alan Yeo, and Carol Cao, and Alain Charest, and Vassiliki A Boussiotis
February 1993, International journal of oncology,
Anthos Christofides, and Laura Strauss, and Alan Yeo, and Carol Cao, and Alain Charest, and Vassiliki A Boussiotis
January 2020, Technology in cancer research & treatment,
Anthos Christofides, and Laura Strauss, and Alan Yeo, and Carol Cao, and Alain Charest, and Vassiliki A Boussiotis
August 1992, Laboratory investigation; a journal of technical methods and pathology,
Anthos Christofides, and Laura Strauss, and Alan Yeo, and Carol Cao, and Alain Charest, and Vassiliki A Boussiotis
August 1978, International journal of cancer,
Copied contents to your clipboard!